Discovery in worms by Queen's researchers points to more targeted cancer treatment

November 10, 2009

Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment.

"When cancer hijacks a healthy system, it can create tumors by causing cells to divide when they shouldn't," says Ian Chin-Sang, a developmental biologist at Queen's and lead researcher on the study. "Certain genes control the normal movement and growth of cells, and by studying how these genes interact, we can understand what is abnormal when cancer is present."

There is an important gene in humans called PTEN that acts as a tumor suppressor. When the PTEN gene function is lost, it can lead to cancers. For example, 70-80 per cent of all prostate cancers have lost PTEN function. Another gene family, called Eph receptors, often shows high levels in cancers, but a connection between PTEN and Eph Receptors in cancer formation has never been shown. The Queen's study shows the remarkable relationship between these genes in worms.

When the research team increased Eph receptor levels in worms, the PTEN levels diminished and the worms died prematurely. When they decreased the Eph receptor level in the worm, the PTEN levels went up and the worm lived longer than normal. The team believes the same principals are applicable to humans.

"Obviously humans and worms look very different," states Professor Chin-Sang, "but at a molecular level, they are very similar. In some instances, like the ones we are studying, the cellular mechanisms are so similar that the human genes can replace the worm's gene."

The next step is to take a closer look at the interaction of these two genes in humans. The findings could lead to exciting breakthroughs in cancer treatment.

"There is a drug used in the treatment of breast cancer that some women develop a resistance to," adds Professor Chin-Sang. "Those same women have also lost their PTEN. Perhaps their Eph is overactive, and that has made the PTEN go down. The research on the worm may therefore provide a useful drug target for therapeutic intervention of breast cancer. In fact, this worm is becoming a bit of a scientific celebrity. Studies on this worm have won researchers three Nobel prizes in the last seven years."
-end-
Professor Chin-Sang's team includes Sarah Brisbin, Jun Liu, Jeff Boudreau, Jimmy Peng and Marie Evangelista from the Queen's Biology Department. The research was supported by the National Cancer Institute of Canada and Canadian Institutes of Health Research. The study is published online in the journal Developmental Cell, and was recently highlighted in Science.

Queen's University

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.